Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans.
about
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasisHigh-Density Lipoproteins: Nature's Multifunctional NanoparticlesWill Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?JTT-705: is there still future for a CETP inhibitor after torcetrapib?Is it time to modify the reverse cholesterol transport model?Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic miceAlpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects.Tangier disease: epidemiology, pathophysiology, and management.Pathways by which reconstituted high-density lipoprotein mobilizes free cholesterol from whole body and from macrophagesThe HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?The Role of PPARĪ± Activation in Liver and Muscle.High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis.Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a reviewA new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in miceA PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I.Alginic acid cell entrapment: a novel method for measuring in vivo macrophage cholesterol homeostasis.Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHAEffects of Liuwei Dihuang Granule ([symbols; see text]) on the outcomes of in vitro fertilization pre-embryo transfer in infertility women with Kidney-yin deficiency syndrome and the proteome expressions in the follicular fluid.Recombinant apolipoprotein A-I(Milano): a novel agent for the induction of regression of atherosclerotic plaques.Molecular regulation of HDL metabolism and function: implications for novel therapies.Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal womenBiologic therapies for dyslipidemia.HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease.Future therapeutic directions in reverse cholesterol transport.Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano)The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory propertiesNicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.Shifting gears: liver SR-BI drives reverse cholesterol transport in macrophages.Reverse cholesterol transport and cholesterol efflux in atherosclerosis.Therapeutic use of the high-density lipoprotein protein and peptides.Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels.High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease.Direct Measurement of the Structure of Reconstituted High-Density Lipoproteins by Cryo-EM.High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease.PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease.
P2860
Q24541529-8FAB93C7-81C5-417C-949C-45EA3E52F418Q28077290-F7A0274C-A57C-406A-969E-DE7296E46395Q28080768-E8807CD5-0AD1-4356-8777-20DB9726DEB7Q28294797-3CD46680-D991-4464-9A3A-B4D9BB523B94Q28363458-ADF1DCBF-359D-4C68-BE43-576128B9C68CQ28593616-DD248EA7-D494-47DA-A69A-91F09816FEE7Q33232282-15238E5E-CCFD-4977-80AC-231EB9DBBC24Q33402921-D90F6FDE-EABD-45A5-B852-C6404469CB2AQ33743839-E5A77485-7320-4875-8FE6-414B9566AC1CQ33993233-58DD4389-DE56-48BC-979F-085029D1509BQ34106233-50FA4F86-7BC7-420C-A702-8E35DFA31B60Q34107511-1C417CD7-3813-4BF7-A4E6-42710EB13195Q34155049-66FC2144-151E-4A1A-AD8D-CD4B17DCE3E1Q34181607-1C44D265-5062-477F-B5E7-75F8CB1905ECQ34238630-F15F4F35-EA22-4572-8B38-3C63B485FCA0Q34559952-5ED7EA0D-5A28-4763-B2BA-2F60FAB007D6Q34827947-C5F71101-9C72-4A94-852B-A18DA26B9B00Q35014329-16C70F00-10E1-4328-A3A6-B1C20565DF6DQ35120961-C4E446B2-ADFE-4C33-81ED-F59554AF59FAQ35143246-A1F84F0E-E313-4F55-82CA-1E7069109D8BQ35170625-B638B3A1-4B2A-4B7A-92BE-724A846397D8Q35191066-E3880E7C-9D0E-412B-A31B-8DF5255193CEQ35203793-9F872DA8-5038-4E05-899E-E868652DE2CAQ35590298-C8D7EB90-A0BB-4490-8419-1AE13A1B6A51Q35590308-65C4400C-753C-416B-AA38-C5CDF2FACE85Q35602792-D8055815-963C-4487-A0D4-C7F71DABE00FQ35754375-7B2C9EA6-6E15-43D1-A950-A2149DE22CA2Q35860010-492C2545-8130-44F5-9F4A-57F21105BBFBQ35860029-8441518A-FAF6-47D4-B7A0-7C8E70D0FC3AQ35893272-C73DDD47-5DCD-4F34-B657-0F7593D98701Q35994365-17D6C6D8-F569-44AB-8F33-8FCCC618DEA5Q36194119-7EFB0831-A3BB-483D-B6CB-31106C3B2286Q36274982-91B4294F-1919-40F0-A412-DF6E04434135Q36300834-E9868FAE-7F71-4EB7-B05E-3783D5FC8F1EQ36407298-0767A5EF-4E21-4D2E-A015-D7493E852042Q36455881-37A80EF2-AEA6-4ED1-BD4B-51DDF30A00FDQ36539475-FE1A7E7F-D54A-408D-B78D-772B7EBBCD57Q36644225-E078B5CD-85A5-4BE4-87FD-53236263959BQ36766976-9E2033FA-C329-46C5-9B62-C62711BF5ED6Q36861044-607C2E4F-B689-4155-A396-5EF3A82AF8FB
P2860
Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans.
description
1999 nĆ® lÅ«n-bĆ»n
@nan
1999 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ£ÕøÕ½ÕæÕøÕ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
1999 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Ö
Õ£ÕøÕ½ÕæÕøÕ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
1999幓ć®č«ę
@ja
1999幓č«ę
@yue
1999幓č«ę
@zh-hant
1999幓č«ę
@zh-hk
1999幓č«ę
@zh-mo
1999幓č«ę
@zh-tw
1999幓č®ŗę
@wuu
name
Stimulation of fecal steroid e ...... olesterol transport in humans.
@ast
Stimulation of fecal steroid e ...... olesterol transport in humans.
@en
Stimulation of fecal steroid e ...... olesterol transport in humans.
@nl
type
label
Stimulation of fecal steroid e ...... olesterol transport in humans.
@ast
Stimulation of fecal steroid e ...... olesterol transport in humans.
@en
Stimulation of fecal steroid e ...... olesterol transport in humans.
@nl
prefLabel
Stimulation of fecal steroid e ...... olesterol transport in humans.
@ast
Stimulation of fecal steroid e ...... olesterol transport in humans.
@en
Stimulation of fecal steroid e ...... olesterol transport in humans.
@nl
P2093
P356
P1433
P1476
Stimulation of fecal steroid e ...... olesterol transport in humans.
@en
P2093
Carlson LA
Miettinen TA
P304
P356
10.1161/01.CIR.100.6.594
P407
P577
1999-08-01T00:00:00Z